Trxade Group Generates Record Revenues in Third Quarter of 2019 Revenue Growth of 173% to $2.311 Million Operating Income Growth of 94% to $177,853 7 th straight quarter of positive operating income Shareholder Equity in

Group Generates Record Revenues in Third Quarter of 2019

Growth of 173% to $2.311 Million

Income Growth of 94% to $177,853

straight quarter of positive operating income

Equity increased to $3.89mil

FL (Access wire) - October 31st, 2019 - Trxade Group, Inc. (OTCQB: TRXD) ("Trxade"

or the "Company"), an integrated pharma supply chain and care platform, announced today its financial results for

its third quarter ended September 30, 2019, and provided a business update.

Sees Continuing Strong Revenue Growth and Profitability in 2019

the third quarter of 2019, we made excellent progress in our core proprietary B2B trading platform www.trxade.com, which

enables independent pharmacies to purchase drugs at discount prices compared to their primaries, enabling us to experience top

and bottom line growth," commented, Suren Ajjarapu, Chairman and Chief Executive Officer of Trxade Group, who continued,

"Additionally, we are investing in core infrastructure for our B-to-C business in our wholesale, e-commerce and delivery

capabilities as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing

medication. Accordingly, I am optimistic that our new product lines will generate profitability."

Results for the Third Quarter Ended September 30, 2019:

for the three months ended September 30, 2019 were $2,311,425 vs. $847,471 in the prior year's quarter, an increase of 173%,

and a 21% sequential increase over the second quarter ended June 30, 2019. The revenue growth was primarily attributable to the

acquisition of our wholly-owned subsidiary Community Specialty Pharmacy, LLC, and an increase of fee income generated from the

Company's web-based supplier-to-pharmacy trading platform (www.trxade.com).

profit for the three months ended September 30, 2019 was $1,310,509, resulting in a gross margin of 56.7%, compared to $845,126

and 99.7% for the three months ended September 30, 2018. The increase in gross profit reflected a sales mix with greater revenue

from specialty pharmaceutical sales, which carries a higher cost of sales, reflecting the lower margins, than the Company's

other revenue sources.

and administrative expenses increased to $1,132,656 in the third quarter of 2019, compared with $753,297 in the prior year's

income increased for the third quarter of 2019 to $177,853, versus $91,829 in the prior year's quarter.

income for the three months ended September 30, 2019, was $27,565, a decrease as compared to net income of $94,249, for the same

period in 2018. The decrease was primarily due to a one time investment loss of $162,178. Earnings per share (EPS) for the three

months period ended September 30, 2019 were $0.00, as compared to $0.00 for the same period in 2018.

September 30, 2019, Trxade had $3,359,288 of cash, $622,552 of debt and 38.6 million shares issued and outstanding.

Results for the Nine Months Ended September 30, 2019:

for the nine months ended September 30, 2019 were $5,740,361 vs. $2,538,082 for the nine months ended September 30, 2018, an increase

of 126%. The revenue growth was primarily attributable to the acquisition of our wholly-owned subsidiary Community Specialty Pharmacy,

LLC, and an increase of fee income generated from the Company's web-based supplier-to-pharmacy trading platform (www.trxade.com).

profit for the nine months ended September 30, 2019 was $3,620,467, resulting in a gross margin of 63%, compared to $2,535,737

and 99.5% for the nine months ended September 30, 2018. This increase reflected a sales mix with greater revenue from Specialty

pharmaceutical sales, which carries a higher cost of sales, reflecting the lower margin, than the Company's other revenue

and administrative expenses increased to $3,138,150 for the nine months ended September 30, 2019, compared with $2,313,734 for

the nine months ended September 30, 2018.

Income increased for the nine months ended September 30, 2019 to $482,317, versus $222,003 in the nine months ended September

income for the nine months ended September 30, 2019, was $210,775, compared to net income of $197,031, for the same period in

2018. The improvement in net income was primarily due to increasing revenue and gross profit contributed from Community Specialty

Pharmacy and an increase in fee income generated from the Company's web-based supplier-to-pharmacy trading platform (www.trxade.com).

The resulting EPS for the nine month period ended September 30, 2019 was $0.01, as compared to $0.01 for the same period in 2018.

in Tampa, Florida, Trxade Group, Inc. (OTCQB: TRXD) is an integrated drug procurement, delivery and healthcare platform

that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. Founded in 2010, Trxade Group

is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,000 registered pharmacists buying

over $120M annually, licensed Wholesale and Mail Order Pharmacy capabilities, including Delivmeds, as well as the newly acquired

assets of Bonum Health. For additional information, please visit us at http://www.trxade.com, http://www.delivmeds.com,

and http://www.bonumhealth.com.

statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Our actual results, performance or achievements may differ materially from those expressed

or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words

such as "may," "could," "expect," "intend," "plan," "seek,"

"anticipate," "believe," "estimate," "predict," "potential," "continue,"

"likely," "will," "would" and variations of these terms and similar expressions, or the negative

of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that,

while considered reasonable by us and our management, are inherently uncertain. We caution you not to place undue reliance on

any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly

any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or

changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update

one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those

or other forward-looking statements. Certain risks and uncertainties applicable to us and our operations are described in the

"Risk Factors" sections of our most recent annual and quarterly reports and in other reports we have filed with the

U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.

Selected Consolidated Financial Data

Three and Nine Months Ended September 30, 2019 and 2018